GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
V

Vuno 338220.KQ · KRW

Health Care · KOSDAQ · 🇰🇷 South Korea

Compare

5,980

+2.57%

Close of 9 Nov 2026, in KRW

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Vuno

Its shares trade on KOSDAQ under the ticker 338220.KQ. It has been listed since 26 February 2021. In the fiscal year to 31 December 2025, it reported revenue of ₩34.85bn and a net loss of ₩5.78bn. At that date it held total assets of ₩50.39bn and shareholders' equity of ₩36.11bn.

VUNO Inc. engages in the development of healthcare algorithms and software solutions. The company is headquartered in Seoul, Seoul. The company went IPO on 2021-02-26. In addition, the Company sells an embolic material product, Nexpear. The firm sells its products in domestic and overseas markets such as Japan, Europe, and the United States.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Health Care Equipment & Supplies
Listed since
26 Feb 2021
Employees
118
Website
vuno.co ↗

Leadership

Pay as last reported

  • Ye Ha LeeChief Executive Officer, Director
  • Jun Hong KimChief Financial Officer
  • Seong Hun JooChief Technology Officer
  • Taek Su KimChief Strategy Officer
  • Mr. Jong Hun ParkDirector

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • VUNO Inc. develops healthcare algorithms and software solutions in Seoul, South Korea.
  • Nexpear, the embolic material product, is sold in Japan, Europe, and the United States.
  • The company has 118 employees focused on healthcare technology innovation.

Weaknesses

  • VUNO Inc. has a limited employee count of 118 in the Health Care sector.
  • The company's domestic market presence in Seoul, South Korea, is not specified.
  • VUNO Inc. relies on a single product, Nexpear, for its embolic material sales.

Opportunities

  • Expanding healthcare algorithm solutions in the European market for VUNO Inc.
  • Growing demand for embolic materials in the United States healthcare sector.
  • Increasing international sales in Japan for VUNO Inc.'s healthcare products.

Threats

  • Competition in the Health Care sector from other South Korean companies.
  • Regulatory changes affecting healthcare algorithms in the European market.
  • Economic downturns impacting healthcare spending in the United States.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.